Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
J. Immunother. Cancer 8:e001145 (2020)
The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Immune Evation ; Review ; T-lymphocytes ; Tumor Escape ; Vaccination; Progressive Multifocal Leukoencephalopathy; Lung-cancer; Therapy; Immunopathology; Immunotherapy; Exhaustion; Expression; Blockade; Defines
ISSN (print) / ISBN
2051-1426
e-ISSN
2051-1426
Quellenangaben
Volume: 8,
Issue: 2,
Article Number: e001145
Publisher
BioMed Central
Publishing Place
London
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Stem Cell Research (ISF)